Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 870

1.

Human NKp44+ group 3 innate lymphoid cells associate with tumor-associated tertiary lymphoid structures in colorectal cancer.

Ikeda A, Ogino T, Kayama H, Okuzaki D, Nishimura J, Fujino S, Miyoshi N, Takahashi H, Uemura M, Matsuda C, Yamamoto H, Takeda K, Mizushima T, Mori M, Doki Y.

Cancer Immunol Res. 2020 Mar 30. pii: canimm.0775.2019. doi: 10.1158/2326-6066.CIR-19-0775. [Epub ahead of print]

PMID:
32229590
2.

Evaluation of risk factors for lymph node metastasis in T2 lower rectal cancer to perform chemoradiotherapy after local resection.

Ushigome H, Ohue M, Kitamura M, Nakatsuka S, Haraguchi N, Nishimura J, Yasui M, Wada H, Takahashi H, Omori T, Miyata H, Yano M, Takiguchi S.

Mol Clin Oncol. 2020 Apr;12(4):390-394. doi: 10.3892/mco.2020.1993. Epub 2020 Feb 3.

3.

Prognostic Significance of C-reactive Protein-to-prealbumin Ratio in Patients with Esophageal Cancer.

Matsunaga T, Miyata H, Sugimura K, Motoori M, Asukai K, Yanagimoto Y, Yamamoto K, Akita H, Nishimura J, Wada H, Takahashi H, Yasui M, Omori T, Ohue M, Fujiwara Y, Yano M.

Yonago Acta Med. 2019 Dec 13;63(1):8-19. doi: 10.33160/yam.2020.02.002. eCollection 2020 Feb.

4.

Prognostic Impact of Postoperative Complications following Salvage Esophagectomy for Esophageal Cancer after Definitive Chemoradiotherapy.

Sugimura K, Miyata H, Shinno N, Ushigome H, Asukai K, Hara H, Hasegawa S, Yamada D, Yamamoto K, Haraguchi N, Nishimura J, Motoori M, Wada H, Takahashi H, Yasui M, Omori T, Ohue M, Yano M.

Oncology. 2020 Mar 10:1-9. doi: 10.1159/000505925. [Epub ahead of print]

PMID:
32155643
5.

Decreased CT-number in the pancreatic parenchyma is a reliable imaging biomarker of the presence of malignancies in patients with high-risk intraductal papillary mucinous neoplasm.

Abe T, Yamada D, Asukai K, Hasegawa S, Tomokuni A, Wada H, Fujii W, Ikezawa K, Fukutake N, Ohkawa K, Shinno N, Hara H, Yanagimoto Y, Takahashi Y, Sugimura K, Yamamoto K, Ushigome H, Haraguchi N, Nishimura J, Yasui M, Omori T, Miyata H, Ohue M, Yano M, Sakon M, Takahashi H.

Pancreatology. 2020 Feb 21. pii: S1424-3903(20)30050-8. doi: 10.1016/j.pan.2020.02.014. [Epub ahead of print]

PMID:
32146046
6.

Rapidly Progressive Acute Kidney Injury Associated with Nivolumab Treatment.

Okawa S, Fujiwara K, Shimonishi A, Matsuura H, Ozeki T, Nishimura J, Kayatani H, Minami D, Shinno Y, Sato K, Ota K, Shibayama T.

Case Rep Oncol. 2020 Feb 6;13(1):85-90. doi: 10.1159/000505235. eCollection 2020 Jan-Apr.

7.

Commentary: Tick-tock.

Nishimura J, Mokadam NA.

J Thorac Cardiovasc Surg. 2020 Jan 31. pii: S0022-5223(20)30245-2. doi: 10.1016/j.jtcvs.2020.01.027. [Epub ahead of print] No abstract available.

PMID:
32087953
8.

Some Gammaproteobacteria are enriched within CD14+ macrophages from intestinal lamina propria of Crohn's disease patients versus mucus.

Sekido Y, Nishimura J, Nakano K, Osu T, Chow CT, Matsuno H, Ogino T, Fujino S, Miyoshi N, Takahashi H, Uemura M, Matsuda C, Kayama H, Mori M, Doki Y, Takeda K, Uchino M, Ikeuchi H, Mizushima T.

Sci Rep. 2020 Feb 19;10(1):2988. doi: 10.1038/s41598-020-59937-w.

9.

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.

Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R.

Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399.

10.

Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).

Schols S, Nunn MA, Mackie I, Weston-Davies W, Nishimura JI, Kanakura Y, Blijlevens N, Muus P, Langemeijer S.

Br J Haematol. 2020 Jan;188(2):334-337. doi: 10.1111/bjh.16305. Epub 2019 Dec 16. No abstract available.

PMID:
31840801
11.

Development of a novel prediction model for recurrent stage II colon cancer.

Takenaka Y, Miyoshi N, Fujino S, Takahashi Y, Nishimura J, Yasui M, Ide Y, Hirose H, Tokuoka M, Ohue M.

Surg Today. 2020 Apr;50(4):389-395. doi: 10.1007/s00595-019-01897-4. Epub 2019 Nov 28.

PMID:
31781952
12.

Gastric cancer cells alter the immunosuppressive function of neutrophils.

Hiramatsu S, Tanaka H, Nishimura J, Yamakoshi Y, Sakimura C, Tamura T, Toyokawa T, Muguruma K, Yashiro M, Hirakawa K, Ohira M.

Oncol Rep. 2020 Jan;43(1):251-259. doi: 10.3892/or.2019.7410. Epub 2019 Nov 20.

PMID:
31746403
13.

Predicting lateral pelvic lymph node metastasis based on magnetic resonance imaging before and after neoadjuvant chemotherapy for patients with locally advanced lower rectal cancer.

Sekido Y, Nishimura J, Fujino S, Ogino T, Miyoshi N, Takahashi H, Uemura M, Haraguchi N, Hata T, Matsuda C, Mizushima T, Murata K, Hasegawa J, Mori M, Doki Y.

Surg Today. 2020 Mar;50(3):292-297. doi: 10.1007/s00595-019-01886-7. Epub 2019 Oct 8.

PMID:
31595366
14.

Colorectal surgery in patients with prior pancreaticoduodenectomy.

Ushigome H, Nishimura J, Takahashi Y, Yasui M, Ohue M, Yamada D, Yamamoto K, Wada H, Takahashi H, Omori T, Miyata H, Takiguchi S.

J Anus Rectum Colon. 2019 Jul 30;3(3):121-127. doi: 10.23922/jarc.2019-005. eCollection 2019.

15.

The Anatomical Pattern of the Proximal Jejunal Vein as a Prognostic Factor in Patients With Pancreatic Head Cancer Treated With Preoperative Chemoradiation Therapy.

Nishimura S, Takahashi H, Akita H, Asukai K, Hasegawa S, Yamada D, Wada H, Hara H, Shinno N, Ushigome H, Haraguchi N, Sugimura K, Yamamoto K, Nishimura J, Yasui M, Omori T, Miyata H, Ohue M, Yano M, Sakon M, Ishikawa O.

Anticancer Res. 2019 Oct;39(10):5821-5830. doi: 10.21873/anticanres.13786.

PMID:
31570487
16.

Prophylactic Effect of Premedication with Intravenous Magnesium on Renal Dysfunction in Preoperative Cisplatin-Based Chemotherapy for Esophageal Cancer.

Kubo Y, Miyata H, Sugimura K, Shinno N, Ushigome H, Yanagimoto Y, Takahashi Y, Yamamoto K, Nishimura J, Wada H, Takahashi H, Yasui M, Omori T, Ohue M, Yano M.

Oncology. 2019;97(6):319-326. doi: 10.1159/000501966. Epub 2019 Sep 25.

PMID:
31553989
17.

Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.

Mizushima T, Ikeda M, Kato T, Ikeda A, Nishimura J, Hata T, Matsuda C, Satoh T, Mori M, Doki Y.

BMC Cancer. 2019 Sep 18;19(1):929. doi: 10.1186/s12885-019-6122-2.

18.

Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.

Sugimura K, Miyata H, Shinno N, Ushigome H, Asukai K, Yanagimoto Y, Hasegawa S, Takahashi Y, Yamada D, Yamamoto K, Nishimura J, Motoori M, Wada H, Takahashi H, Yasui M, Omori T, Ohue M, Yano M.

Oncology. 2019;97(6):348-355. doi: 10.1159/000502342. Epub 2019 Aug 28.

PMID:
31461716
19.

The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study.

Akita H, Takahashi H, Asukai K, Tomokuni A, Wada H, Marukawa S, Yamasaki T, Yanagimoto Y, Takahashi Y, Sugimura K, Yamamoto K, Nishimura J, Yasui M, Omori T, Miyata H, Ochi A, Kagawa A, Soh Y, Taniguchi Y, Ohue M, Yano M, Sakon M.

Clin Nutr ESPEN. 2019 Oct;33:148-153. doi: 10.1016/j.clnesp.2019.06.003. Epub 2019 Jun 21.

PMID:
31451252
20.

Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation.

Höchsmann B, Murakami Y, Osato M, Knaus A, Kawamoto M, Inoue N, Hirata T, Murata S, Anliker M, Eggermann T, Jäger M, Floettmann R, Höllein A, Murase S, Ueda Y, Nishimura JI, Kanakura Y, Kohara N, Schrezenmeier H, Krawitz PM, Kinoshita T.

J Clin Invest. 2019 Dec 2;129(12):5123-5136. doi: 10.1172/JCI123501.

Supplemental Content

Loading ...
Support Center